

09/994,153

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:13:23 ON 07 SEP 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:13:32 ON 07 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2004 HIGHEST RN 740796-45-6

DICTIONARY FILE UPDATES: 6 SEP 2004 HIGHEST RN 740796-45-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\994153.str

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\994153a.str


L2 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR


09/994,153



G1 S,N  
G2 C,O,N  
G3 C,H,O  
G4 O,X  
G5 H,O

Structure attributes must be viewed using STN Express query preparation.

=> d 12  
L2 HAS NO ANSWERS  
L2 STR



G1 S,N  
G2 C,O,N  
G3 C,H,O  
G4 O,X  
G5 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss full  
FULL SEARCH INITIATED 16:14:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1641 TO ITERATE

100.0% PROCESSED 1641 ITERATIONS  
SEARCH TIME: 00.00.01

6 ANSWERS

L3 6 SEA SSS FUL L1

=> s 12 sss full

09/994,153

FULL SEARCH INITIATED 16:15:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1641 TO ITERATE

100.0% PROCESSED 1641 ITERATIONS 6 ANSWERS  
SEARCH TIME: 00.00.01

L4 6 SEA SSS FUL L2

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
311.26	311.47

FULL ESTIMATED COST  
FILE 'CAPLUS' ENTERED AT 16:15:06 ON 07 SEP 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 7 Sep 2004 VOL 141 ISS 11  
FILE LAST UPDATED: 6 Sep 2004 (20040906/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L5 3 L3

=> d 15 1-3 ibib abs hitstr

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:585086 CAPLUS  
DOCUMENT NUMBER: 138:89769  
TITLE: Arylpiperazine substituted heterocycles as Selective  $\alpha$ 1a adrenergic antagonists  
AUTHOR(S): Khatuya, Haripada; Hutchings, Richard H.; Kuo, Gee-Hong; Pulito, Virginia L.; Jolliffe, Linda K.; Li, Xiaobing; Murray, William V.  
CORPORATE SOURCE: Drug Discovery Research, Johnson & Johnson  
Pharmaceutical Research and Development LLC, Raritan, NJ, 08869, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(17), 2443-2446  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 138:89769  
GI



AB Antagonists of the  $\alpha$ 1-adrenergic receptors ( $\alpha$ 1-ARs) are useful for the treatment of benign prostatic hyperplasia. A series of potent and subtype-selective  $\alpha$ 1-AR antagonists has been synthesized, e.g. I, displaying in vitro binding affinity in the low the nanomolar range.


IT **483987-66-2P 483987-69-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylpiperazine substituted heterocycles as selective  $\alpha$ 1 adrenergic antagonists)


RN 483987-66-2 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 483987-69-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:543677 CAPLUS

DOCUMENT NUMBER: 138:39156

TITLE: Novel thiophene derivatives for the treatment of benign prostatic hyperplasia

AUTHOR(S): Khatuya, Haripada; Pulito, Virginia L.; Jolliffe, Linda K.; Li, Xiaobing; Murray, William V.

CORPORATE SOURCE: Drug Discovery Research, Johnson & Johnson Pharmaceutical Research and Development LLC, Raritan, NJ, 08869, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002),

12(16), 2145-2148

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER:

Elsevier Science Ltd.

DOCUMENT TYPE:

Journal


LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 138:39156

GI



AB The syntheses and biol. activities of a novel series of 2,4- and 2,5-disubstituted thiophenes, e.g. I, are reported. These analogs have shown excellent affinity and selectivity against  $\alpha$ 1-adrenoreceptor subtypes.


IT **223254-07-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(novel thiophene derivs. for the treatment of benign prostatic hyperplasia)

RN 223254-07-7 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)




IT **478811-76-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel thiophene derivs. for the treatment of benign prostatic hyperplasia)

RN 478811-76-6 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:271334 CAPLUS

DOCUMENT NUMBER: 130:296696

TITLE: Preparation of arylpiperazines for the treatment of benign prostatic hyperplasia.

INVENTOR(S): Hutchings, Richard H.; Khatuya, Haripada; Kuo, Gee-Hong; Li, Xiaobing; Murray, William V.; Prouty, Catherine

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919299	A1	19990422	WO 1998-US21470	19981009
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305353	AA	19990422	CA 1998-2305353	19981009
AU 9910783	A1	19990503	AU 1999-10783	19981009
EP 1025085	A1	20000809	EP 1998-953393	19981009
EP 1025085	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001519413	T2	20011023	JP 2000-515872	19981009
US 6384035	B1	20020507	US 1998-169571	19981009
EP 1273572	A1	20030108	EP 2002-78537	19981009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 235466	E	20030415	AT 1998-953393	19981009
ES 2195410	T3	20031201	ES 1998-953393	19981009
HK 1026701	A1	20031121	HK 2000-105885	20000919
US 2002165219	A1	20021107	US 2001-994153	20011126
PRIORITY APPLN. INFO.:			US 1997-61618P	P 19971009
			EP 1998-953393	A3 19981009
			US 1998-169571	A3 19981009
			WO 1998-US21470	W 19981009

OTHER SOURCE(S): MARPAT 130:296696

GI



AB Title compds. [I; R1 = H, halo, alkoxy, OH, alkyl; R2 = (substituted) alkyl, Ph, phenylalkyl; R3 = H, alkoxy, carbonyl, alkyl, hydroxyalkyl, CHO, Ac, amido, O; A = oxazolyliidene, thienylene, isoxazolidene, COCH2CO, COCH2CHOH, COCH:CH, CHOHCH2CHOH, etc.; B = H, O; Z = (CH2)n, etc.; n = 1-5; dotted lines = double bonds when R3, B = O], were prepared Thus, chloroacetone was refluxed with 1-(2-isopropoxyphenyl)piperazine and K2CO3 for 1 day to give 1-(2-isopropoxyphenyl)-4-(2-oxopropyl)piperazine. The latter was stirred with 1-(ethoxycarbonylmethyl)-2-piperidone and NaH in THF to give title compound (II), which showed bound to adrenergic  $\alpha$ 1a,  $\alpha$ 1b, and  $\alpha$ 1c receptors with IC50 = 417 nM, >10000 nM, and 6043 nM, resp.


IT 223253-82-5P 223253-94-9P 223254-07-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylpiperazines for the treatment of benign prostatic hyperplasia)

RN 223253-82-5 CAPLUS


CN 4-Oxazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 223253-94-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/994,153



RN 223254-07-7 CAPLUS  
CN 2-Thiophenecarboxaldehyde, 5-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 14

L6 3 L4

=> d 16 1-3 ibib abs hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:585086 CAPLUS

DOCUMENT NUMBER: 138:89769

TITLE: Arylpiperazine substituted heterocycles as Selective  
 $\alpha$ 1a adrenergic antagonists

AUTHOR(S): Khatuya, Haripada; Hutchings, Richard H.; Kuo,  
Gee-Hong; Pulito, Virginia L.; Jolliffe, Linda K.; Li,  
Xiaobing; Murray, William V.

CORPORATE SOURCE: Drug Discovery Research, Johnson & Johnson  
Pharmaceutical Research and Development LLC, Raritan,  
NJ, 08869, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002),  
12(17), 2443-2446

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:89769

GI





AB Antagonists of the  $\alpha_1$ -adrenergic receptors ( $\alpha_1$ -ARs) are useful for the treatment of benign prostatic hyperplasia. A series of potent and subtype-selective  $\alpha_1$ -AR antagonists has been synthesized, e.g. I, displaying in vitro binding affinity in the low the nanomolar range.


IT **483987-66-2P 483987-69-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylpiperazine substituted heterocycles as selective  $\alpha_1$  adrenergic antagonists)


RN 483987-66-2 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 483987-69-5 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:543677 CAPLUS

DOCUMENT NUMBER: 138:39156

TITLE: Novel thiophene derivatives for the treatment of benign prostatic hyperplasia


AUTHOR(S): Khatuya, Haripada; Pulito, Virginia L.; Jolliffe, Linda K.; Li, Xiaobing; Murray, William V.

CORPORATE SOURCE: Drug Discovery Research, Johnson & Johnson Pharmaceutical Research and Development LLC, Raritan, NJ, 08869, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2145-2148

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 138:39156  
 GI



AB The syntheses and biol. activities of a novel series of 2,4- and 2,5-disubstituted thiophenes, e.g. I, are reported. These analogs have shown excellent affinity and selectivity against  $\alpha$ 1-adrenoreceptor subtypes.


IT **223254-07-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(novel thiophene derivs. for the treatment of benign prostatic hyperplasia)

RN 223254-07-7 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




IT **478811-76-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel thiophene derivs. for the treatment of benign prostatic hyperplasia)

RN 478811-76-6 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:



21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:271334 CAPLUS  
 DOCUMENT NUMBER: 130:296696  
 TITLE: Preparation of arylpiperazines for the treatment of benign prostatic hyperplasia.  
 INVENTOR(S): Hutchings, Richard H.; Khatuya, Haripada; Kuo, Gee-Hong; Li, Xiaobing; Murray, William V.; Prouty, Catherine  
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA  
 SOURCE: PCT Int. Appl., 84 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919299	A1	19990422	WO 1998-US21470	19981009
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305353	AA	19990422	CA 1998-2305353	19981009
AU 9910783	A1	19990503	AU 1999-10783	19981009
EP 1025085	A1	20000809	EP 1998-953393	19981009
EP 1025085	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001519413	T2	20011023	JP 2000-515872	19981009
US 6384035	B1	20020507	US 1998-169571	19981009
EP 1273572	A1	20030108	EP 2002-78537	19981009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 235466	E	20030415	AT 1998-953393	19981009
ES 2195410	T3	20031201	ES 1998-953393	19981009
HK 1026701	A1	20031121	HK 2000-105885	20000919
US 2002165219	A1	20021107	US 2001-994153	20011126
PRIORITY APPLN. INFO.:				
			US 1997-61618P	P 19971009
			EP 1998-953393	A3 19981009
			US 1998-169571	A3 19981009
			WO 1998-US21470	W 19981009
OTHER SOURCE(S): MARPAT 130:296696				
GI				



AB Title compds. [I; R1 = H, halo, alkoxy, OH, alkyl; R2 = (substituted) alkyl, Ph, phenylalkyl; R3 = H, alkoxycarbonyl, alkyl, hydroxyalkyl, CHO, Ac, amido, O; A = oxazolylidene, thienylene, isoxazolidene, COCH2CO, COCH2CHOH, COCH:CH, CHOHCH2CHOH, etc.; B = H, O; Z = (CH2)n, etc.; n = 1-5; dotted lines = double bonds when R3, B = O], were prepared Thus, chloroacetone was refluxed with 1-(2-isopropoxyphenyl)piperazine and K2CO3 for 1 day to give 1-(2-isopropoxyphenyl)-4-(2-oxopropyl)piperazine. The latter was stirred with 1-(ethoxycarbonylmethyl)-2-piperidone and NaH in THF to give title compound (II), which showed bound to adrenergic  $\alpha_1$ ,  $\alpha_1b$ , and  $\alpha_1c$  receptors with IC50 = 417 nM, >10000 nM, and 6043 nM, resp.


IT 223253-82-5P 223253-94-9P 223254-07-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylpiperazines for the treatment of benign prostatic hyperplasia)


RN 223253-82-5 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 223253-94-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 223254-07-7 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT